Skip to main content
TipRanks
Go Ultimate75% OFF

PDS Biotechnology (EU6) Stock Price & Analysis

2 Followers

EU6 Stock Chart & Stats

€0.76€0.00(0.00%)
At close: 5:30 PM GMT+1
€0.5€1€1.5Aug 17Aug 28Sep 15Sep 28Oct 12Oct 23Nov 11
Day’s Range
EUR 0.76 - EUR 0.86
52-Week Range
EUR 0.17 - EUR 1.59
Previous Close
EUR 0.76
Volume
N/A
Average Volume (3M)
1,226
Market Cap
EUR 75.05M
Enterprise Value
EUR 38.79M
Total Cash (Recent Filing)
EUR 15.25B
Total Debt (Recent Filing)
EUR 33.52M
Price to Earnings (P/E)
―
Beta
0.40
Next Earnings
Apr 01, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Pipeline Progress

Encouraging Phase 2 outcomes for PDS0301 in difficult-to-treat metastatic colorectal cancer provide clinical validation for the lead program. The planned registrational Phase 3 path could improve partnering prospects and create a durable value driver if efficacy is confirmed.

PDS0101 Efficacy And Partner Interest

PDS0101 combines differentiated clinical results with identifiable external interest from NantWorks. A potential licensing partnership could help fund Phase 3 development, reduce the company’s burden of advancing the program alone, and validate the platform’s commercial relevance.

Debt Retirement And Strategic Funding

Retiring the Yorkville obligation simplifies near-term liabilities, while the PIPE provides capital for working needs and clinical development. This financing and strategic relationship improve operational continuity and support advancement of PDS0301 toward later-stage trials.

Bears Say

Pre-Revenue Losses

PDS Biotechnology has not yet demonstrated a commercial revenue base and continues to report substantial losses. Until a candidate is approved or partnered economics become meaningful, the business lacks recurring operating income and remains dependent on successful clinical and regulatory execution.

Persistent Cash Burn

Ongoing negative operating and free cash flow shows that the company is not self-funding its research and development activities. Continued dependence on financing leaves execution tied to capital availability and can constrain the pace of pipeline advancement over coming quarters.

Financing Flexibility Constraints

Tighter lender protections reduce management’s discretion over newly raised capital and can limit flexibility in allocating funds among debt repayment, operations, and clinical programs. This raises the importance of future financing structure and milestone timing for sustained development.

PDS Biotechnology News

EU6 FAQ

What was PDS Biotechnology’s price range in the past 12 months?
PDS Biotechnology lowest stock price was €0.17 and its highest was €1.59 in the past 12 months.
What is PDS Biotechnology’s market cap?
PDS Biotechnology’s market cap is €75.05M.
When is PDS Biotechnology’s upcoming earnings report date?
PDS Biotechnology’s next earnings report is estimated for Apr 01, 2027 (not yet confirmed), which is in 133 days.
How were PDS Biotechnology’s earnings last quarter?
PDS Biotechnology released its earnings results on Nov 13, 2026. The company reported -€0.1 earnings per share for the quarter, missing the consensus estimate of -€0.082 by -€0.018.
Is PDS Biotechnology overvalued?
According to Wall Street analysts PDS Biotechnology’s price is currently Undervalued.
Does PDS Biotechnology pay dividends?
PDS Biotechnology does not currently pay dividends.
What is PDS Biotechnology’s EPS estimate?
PDS Biotechnology’s EPS estimate is -0.05.
How many shares outstanding does PDS Biotechnology have?
PDS Biotechnology has 105,005,430 shares outstanding.
What happened to PDS Biotechnology’s price movement after its last earnings report?
PDS Biotechnology reported an EPS of -€0.1 in its last earnings report, missing expectations of -€0.082. Following the earnings report the stock price went down -2.5%.
Which hedge fund is a major shareholder of PDS Biotechnology?
Currently, no hedge funds are holding shares in DE:EU6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology